News >

Overcoming Resistance to HER2-Targeted Therapy in Breast Cancer

Angelica Welch
Published: Wednesday, Mar 29, 2017

Mark D. Pegram, MD

Mark D. Pegram, MD

There are several proposed mechanisms of resistance being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer. The strengthening of antibody dependent cell-mediated cytotoxicity (ADCC) shows promise in clinical trials, but there also is potential benefit in exploring other avenues, such as mutations of the PI3-kinase gene and PTEN, parallel pathway activation, antibody-drug conjugates, and the combination of checkpoint inhibitors with HER2 antibodies, according to Mark D. Pegram, MD, who gave a presentation on the subject at the 2017 Miami Breast Cancer Conference (MBCC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication